Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Michael Levy & Maureen A Mealy. (2021) B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20. ImmunoTargets and Therapy 10, pages 325-331.
Read now
Read now
Articles from other publishers (29)
Raluca Ioana Teleanu, Adelina-Gabriela Niculescu, Oana Aurelia Vladacenco, Eugenia Roza, Radu-Stefan Perjoc & Daniel Mihai Teleanu. (2023) The State of the Art of Pediatric Multiple Sclerosis. International Journal of Molecular Sciences 24:9, pages 8251.
Crossref
Crossref
Panagiotis Kanatas, Ioannis Stouras, Leonidas Stefanis & Panos Stathopoulos. (2022) B-Cell-Directed Therapies: A New Era in Multiple Sclerosis Treatment. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 50:3, pages 355-364.
Crossref
Crossref
Ramdas Bhat, Preeti Shanbhag & Ramakrishna Shabaraya. (2023) A Comprehensive Review of Anti-CD20 Monoclonal Antibodies in Multiple Sclerosis. International Journal of Pharmaceutical And Phytopharmacological Research 13:5, pages 19-24.
Crossref
Crossref
Danica Michaličková, Hatice Kübra Öztürk & Ondřej Slanař. 2023. Translational Neuroimmunology, Volume 8. Translational Neuroimmunology, Volume 8
129
143
.
Marta Tejera-Alhambra & Silvia Sánchez-Ramón. 2023. Translational Neuroimmunology, Volume 8. Translational Neuroimmunology, Volume 8
11
26
.
Sinali O. Seneviratne, Mark Marriott, Sudarshini Ramanathan, Wei Yeh, Fabienne Brilot-Turville, Helmut Butzkueven & Mastura Monif. (2022) Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. BMC Neurology 22:1.
Crossref
Crossref
Erica Costantini, Eva Masciarelli, Laura Casorri, Marco Di Luigi & Marcella Reale. (2022) Medicinal herbs and multiple sclerosis: Overview on the hard balance between new therapeutic strategy and occupational health risk. Frontiers in Cellular Neuroscience 16.
Crossref
Crossref
Oscar Palomares, Dirk Elewaut, Peter M. Irving, Xavier Jaumont & Paolo Tassinari. (2022) Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?. Allergy 77:11, pages 3293-3308.
Crossref
Crossref
Alexander J. Kwiatkowski, Eric Y. Helm, Joshua M. Stewart, Theodore T. Drashansky, Jonathan J. Cho, Dorina Avram & Benjamin G. Keselowsky. (2022) Treatment with an antigen-specific dual microparticle system reverses advanced multiple sclerosis in mice. Proceedings of the National Academy of Sciences 119:43.
Crossref
Crossref
Bruce AC Cree. (2022) All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes. Multiple Sclerosis Journal 28:12, pages 1843-1844.
Crossref
Crossref
Massimo Filippi, Romano Danesi, Tobias Derfuss, Martin Duddy, Paolo Gallo, Ralf Gold, Eva Kubala Havrdová, Barbara Kornek, Francesco Saccà, Mar Tintoré, Jörg Weber & Maria Trojano. (2021) Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. Journal of Neurology 269:3, pages 1670-1677.
Crossref
Crossref
Leoni RolfesMarc PawlitzkiSteffen Pfeuffer, Christopher NelkeAnke LuxRefik PulChristoph Kleinschnitz, Konstanze KleinschnitzRebeca RogallKatrin PapeStefan BittnerFrauke Zipp, Clemens WarnkeYasemin GoereciMichael SchroeterJens IngwersenOrhan Aktas, Luisa Klotz, Tobias RuckHeinz WiendlSven G. Meuth. (2021) Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. Neurology Neuroimmunology & Neuroinflammation 8:5.
Crossref
Crossref
Judong Kim, S.M. Touhidul Islam, Fei Qiao, Avtar K. Singh, Mushfiquddin Khan, Jeseong Won & Inderjit Singh. (2021) Regulation of B cell functions by S-nitrosoglutathione in the EAE model. Redox Biology 45, pages 102053.
Crossref
Crossref
Amit Bar-Or, Susan M. O’Brien, Michael L. Sweeney, Edward J. Fox & Jeffrey A. Cohen. (2021) Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. CNS Drugs 35:9, pages 985-997.
Crossref
Crossref
Rosa Margareta BrandVerena FriedrichJolien Diddens, Monika PfallerFrancesca Romana de FranchisHelena RadbruchBernhard Hemmer, Katja Steiger & Klaus Lehmann-Horn. (2021) Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue. Neurology Neuroimmunology & Neuroinflammation 8:4.
Crossref
Crossref
Tyler Ellis Smith & Ilya Kister. (2021) Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Current Neurology and Neuroscience Reports 21:7.
Crossref
Crossref
Shin-Young Na & Gurumoorthy Krishnamoorthy. (2021) Targeted Expression of Myelin Autoantigen in the Periphery Induces Antigen-Specific T and B Cell Tolerance and Ameliorates Autoimmune Disease. Frontiers in Immunology 12.
Crossref
Crossref
Natalia Gonzalez Caldito, Afsaneh Shirani, Amber Salter & Olaf Stuve. (2020) Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. Multiple Sclerosis Journal 27:7, pages 1066-1076.
Crossref
Crossref
Masoumeh Cheshmavar, Omid Mirmosayyeb, Negin Badihian, Shervin Badihian & Vahid Shaygannejad. (2020) Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial. Acta Neurologica Scandinavica 143:2, pages 178-187.
Crossref
Crossref
Rawan Hamdan Alenazy, Mohammed Majed S Abualshamat, Fahad Sh S Dh Alqahs, Abdullah F N Almutairi, Mohammed Khalid Moslih Alharbi, Bandar Mohammad Alkhuraimi, Yahya Abdulrahman Dhamiri, Mohammed Munir Abdullah Alshahrani, Kholoud Mesfer Alshahrani & Mohammed Abdullah Alghamdi. (2021) The Role of Ocrelizumab in Multiple Sclerosis Treatment. Archives Of Pharmacy Practice 12:3, pages 117-120.
Crossref
Crossref
Mustafa Mohammed Al Brahim, Omar Muhammed Aldosari, Saeed Ali Saeed Alyahya, Faisal Saeed Mohammad Alahmari, Laila Zawan Ali Almalki, Abdulaziz Muqbil Faleh Alshammari, Ahmed Khalifah Albahrani, Tahani Abduljalil Albahrani, Saad Zaid Aljabr & Faleh Mansour Alrashdi. (2021) Vitamin D and Multiple Sclerosis; Is There a Real Association?. International Journal Of Pharmaceutical Research And Allied Sciences 10:2, pages 129-133.
Crossref
Crossref
Gunnar Houen, Nicole Hartwig Trier & Jette Lautrup Frederiksen. (2020) Epstein-Barr Virus and Multiple Sclerosis. Frontiers in Immunology 11.
Crossref
Crossref
Björn Evertsson, Tammy Hoyt, Angel Christensen, Faiez AL Nimer, John Foley & Fredrik Piehl. (2020) A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 6:4, pages 205521732096450.
Crossref
Crossref
Sebastian Rauer, Muna-Miriam Hoshi, Refik Pul, Mathias Wahl, Matthias Schwab, Judith Haas, Gisa Ellrichmann, Markus Krumbholz, Björn Tackenberg, Kai-Uwe Saum, Fabian Buck, Jost Leemhuis, Anita Kretschmann & Orhan Aktas. (2020) Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany. Clinical Neurology and Neurosurgery 197, pages 106142.
Crossref
Crossref
Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef & Stephen Tomlinson. (2020) Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?. Frontiers in Immunology 11.
Crossref
Crossref
Laura D Chin & Mohn’d AbuHilal. (2020) Ocrelizumab-induced alopecia areata—A series of five patients from Ontario, Canada: A case report. SAGE Open Medical Case Reports 8, pages 2050313X2091961.
Crossref
Crossref
Pitchaya Wanleenuwat & Piotr Iwanowski. (2019) Role of B cells and antibodies in multiple sclerosis. Multiple Sclerosis and Related Disorders 36, pages 101416.
Crossref
Crossref
George Vartzelis, Despoina Maritsi, Maria Nikolaidou, Anastasia Garoufi & Constantinos Kilidireas. (2019) Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis. Case Reports in Pediatrics 2019, pages 1-3.
Crossref
Crossref
O. V. Boyko, I. I. Choroshilova, S. V. Petrov, M. V. Melnikov & A. N. Boyko. (2019) Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:10, pages 120.
Crossref
Crossref